Bausch Health stock soars after company says rival application for generic version of its IBS drug can't be approved until 2029
Bausch Health Cos. Inc. (BHC.T) on Wednesday said a U.S. district court stuck with an earlier judgment that prevented an application for a rival generic version of its Xifaxan irritable bowel syndrome drug from getting FDA approval until 2029, sending shares higher during regular and after-hours trade. The company and its gastroenterology business Salix Pharmaceuticals said in a statement that the U.S. District Court of Delaware denied a motion by Norwich Pharmaceuticals -- which wants to develop a generic version of the drug -- to alter the court's final judgment on the matter. That judgment keeps the FDA from approving Norwich's abbreviated new drug application for Xifaxan before Oct. 2, 2029. The ruling stems from a patent-infringement lawsuit against Norwich brought by Bausch and Salix in 2020. "It is our long- standing position that the Xifaxan patent claims are valid and infringed by Norwich's (abbreviated new drug application)," Bausch Health Chief Executive Thomas Appio said in a statement on Wednesday. Shares rose 3.4% after hours, after finishing 24.1% higher during regular trading.
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-17-23 1935ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
After Earnings, Is Apple Stock a Buy, a Sell, or Fairly Valued?
-
Uber Earnings: Network Effect Continues to Drive Profitable Growth for Uber
-
Undervalued by 28%, This Stock Is a Buy for Patient Investors
-
10 Best Growth Stocks to Buy for the Long Term
-
The Best Technology Stocks to Buy
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?
-
Disney Earnings: Improved Streaming Results Come at the Expense of Continued Linear Weakness
-
Apple: We Expect New Models and New Chip to Spur Return to iPad Growth